wide
rang
virus
affect
respiratori
tract
gener
divid
virus
primari
site
infect
respiratori
tract
classic
respiratori
virus
includ
influenza
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
parainfluenza
viru
piv
rhinoviru
adenoviru
virus
affect
respiratori
tract
opportunist
ie
herp
simplex
hsv
cytomegaloviru
cmv
measl
focu
articl
antivir
direct
classic
respiratori
virus
excel
review
agent
treatment
hsv
cmv
infect
found
elsewher
howev
signific
effort
invest
novel
antivir
respiratori
virus
often
direct
novel
target
combin
design
increas
potenc
reduc
resist
emerg
therapeut
antibodi
immunomodulatori
agent
select
mitig
immunopatholog
host
respons
agent
advanc
clinic
develop
review
briefli
wherea
detail
review
may
found
elsewher
antivir
drug
current
approv
treat
respiratori
viru
infect
specif
inhibitor
influenza
virus
emerg
new
pathogen
like
middl
east
respiratori
syndrom
coronaviru
also
led
screen
effort
identifi
new
therapeut
ion
channel
allow
hydrogen
ion
flow
viral
particl
result
releas
rna
segment
infect
cell
amantadin
symmetrel
rimantadin
flumadin
symmetr
tricycl
amin
specif
inhibit
replic
influenza
virus
low
concentr
mgml
block
action
protein
use
suscept
strain
agent
effect
prevent
infect
reduc
durat
fever
symptom
use
treatment
although
class
drug
specif
indic
prevent
treatment
influenza
infect
widespread
resist
inhibitor
document
circul
influenza
strain
class
agent
current
recommend
prevent
treatment
influenza
crossresist
agent
occur
result
singl
amino
acid
substitut
transmembran
portion
protein
resist
viru
seem
retain
wildtyp
pathogen
caus
influenza
ill
indistinguish
caus
suscept
strain
drug
achiev
peak
level
hour
ingest
amantadin
rimantadin
come
tablet
syrup
formul
mg
ml
adult
usual
dose
treatment
prevent
influenza
infect
mg
everi
hour
drug
amantadin
excret
unchang
kidney
wherea
rimantadin
undergo
extens
metabol
liver
excret
kidney
result
dose
adjust
renal
dysfunct
requir
common
side
effect
inhibitor
minor
central
nervou
system
complaint
anxieti
difficulti
concentr
insomnia
dizzi
headach
jitteri
gastrointestin
upset
particularli
promin
elderli
renal
failur
patient
receiv
amantadin
may
develop
antimuscarin
effect
orthostat
hypotens
congest
heart
failur
rate
advers
effect
lower
rimantadin
amantadin
given
drugdrug
interact
care
use
coadminist
either
agent
antihistamin
anticholinerg
drug
trimethoprimsulfamethoxazol
triamterenehydrochlorothiazid
quinin
quinidin
monoamin
oxidas
inhibitor
antidepress
minor
tranquil
influenza
b
virus
possess
surfac
glycoprotein
neuraminidas
activ
cleav
termin
sialic
acid
residu
variou
glycoconjug
destroy
receptor
recogn
viral
hemagglutinin
activ
essenti
releas
viru
infect
cell
prevent
viral
aggreg
viral
spread
within
respiratori
tract
oseltamivir
tamiflu
prodrug
activ
carboxyl
laninamivir
inavir
peramivir
rapiacta
peramiflu
zanamivir
relenza
sialic
acid
analogu
potent
specif
inhibit
influenza
b
neuraminidas
competit
revers
interact
activ
enzym
site
oseltamivir
zanamivir
global
avail
wherea
laninamivir
approv
japan
peramivir
approv
china
japan
south
korea
unit
state
laninamivir
octano
prodrug
convert
airway
laninamivir
activ
neuraminidas
inhibitor
retain
concentr
exceed
ic
inhibitori
concentr
influenza
neuraminidas
least
hour
day
singl
inhal
mg
drug
system
absorb
inhal
dose
adjust
indic
renal
hepat
insuffici
laninamivir
octano
current
approv
japan
treatment
prevent
influenza
b
infect
avail
dri
powder
inhal
singl
inhal
mg
daili
day
recommend
prophylaxi
wherea
singl
inhal
mg
individu
greater
equal
year
age
mg
children
less
year
age
recommend
treatment
laninamivir
associ
rapid
time
allevi
influenza
ill
caus
infect
season
viru
substitut
children
compar
standard
oseltamivir
regimen
wherea
studi
adult
show
noninferior
versu
oseltamivir
patient
laninamivir
show
similar
durat
fever
ambulatori
children
compar
patient
treat
zanamivir
among
household
contact
index
patient
influenza
day
laninamivir
mg
daili
associ
protect
efficaci
respect
compar
placebo
common
side
effect
includ
nausea
vomit
diarrhea
dizzi
laninamivir
associ
signific
bronchospasm
respiratori
advers
effect
patient
chronic
respiratori
diseas
oseltamivir
oral
oseltamivir
ethyl
ester
well
absorb
rapidli
cleav
esteras
gastrointestin
tract
liver
blood
bioavail
activ
metabolit
oseltamivir
carboxyl
estim
previous
healthi
person
plasma
elimin
halflif
hour
prolong
elderli
although
dose
adjust
gener
necessari
administr
food
seem
decreas
risk
gastrointestin
upset
without
decreas
bioavail
prodrug
parent
elimin
primarili
unchang
kidney
glomerular
filtrat
anion
tubular
secret
dose
reduc
half
patient
creatinin
clearanc
less
mlmin
reduct
clearanc
less
mlmin
distribut
well
character
human
peak
bronchoalveolar
lavag
middl
ear
fluid
sinu
fluid
level
similar
plasma
level
oseltamivir
indic
prevent
influenza
b
patient
greater
equal
year
old
dose
day
treatment
patient
greater
equal
week
age
influenza
b
twiceaday
dose
oseltamivir
avail
oral
deliveri
oseltamivir
come
tablet
white
tuttifruttiflavor
suspens
oseltamivir
base
final
concentr
mgml
approv
adult
dose
treatment
mg
twice
daili
day
prophylaxi
mg
daili
pediatr
dose
base
weight
outlin
tabl
efficaci
prophylaxi
protect
unvaccin
patient
given
day
week
caution
use
prescrib
oseltamivir
prophylaxi
patient
expos
index
case
prophylaxi
associ
emerg
resist
mutant
empir
therapi
monitor
gener
recommend
case
result
among
ambulatori
adult
uncompl
influenza
b
oseltamivir
mg
twice
daili
day
start
within
first
day
symptom
associ
shorter
time
allevi
uncompl
influenza
ill
hour
shorter
reduct
sever
ill
durat
fever
time
return
normal
activ
quantiti
viral
shed
durat
impair
activ
complic
lead
antibiot
use
particularli
bronchiti
compar
placebo
previous
healthi
adult
pediatr
studi
enrol
children
young
week
age
show
oseltamivir
safe
associ
significantli
reduc
ill
durat
sever
time
resumpt
full
activ
occurr
complic
lead
antibiot
use
particularli
acut
otiti
media
exist
literatur
safeti
efficaci
oseltamivir
hospit
adult
children
suggest
among
highrisk
hospit
individu
benefit
start
antivir
therapi
least
day
symptom
onset
greatest
benefit
patient
start
within
hour
symptom
onset
studi
hospit
adult
suggest
earli
therapi
associ
reduc
incid
lower
respiratori
tract
complic
requir
intens
care
unit
icu
level
care
durat
ill
durat
shed
mortal
durat
therapi
well
studi
data
suggest
longer
durat
therapi
day
may
requir
particularli
critic
ill
patient
pneumonia
viral
replic
lower
airway
correl
quantiti
durat
replic
upper
airway
doubl
treatment
dose
oseltamivir
hospit
patient
influenza
seem
increas
virolog
efficaci
except
perhap
influenza
b
infect
clinic
effect
although
one
icubas
random
control
trial
report
tripl
standard
dose
associ
acceler
viral
rna
clearanc
respiratori
tract
dose
oseltamivir
given
hemodialysi
dose
must
adjust
renal
insuffici
renal
replac
therapi
see
tabl
conflict
data
optim
dose
oseltamivir
pregnant
women
studi
suggest
need
higher
dose
mg
time
day
wherea
other
suggest
dose
adjust
need
current
guidelin
recommend
treat
pregnant
women
influenza
infect
one
approv
neuraminidas
inhibitor
recommend
pediatr
dosag
list
tabl
oral
oseltamivir
gener
well
toler
seriou
endorgan
toxic
found
control
clinic
trial
oseltamivir
associ
nausea
abdomin
discomfort
less
often
emesi
minor
treat
patient
amelior
give
food
dose
infrequ
possibl
advers
event
includ
insomnia
vertigo
fever
postmarket
report
suggest
oseltamivir
may
associ
rare
skin
rash
hepat
dysfunct
thrombocytopenia
addit
report
abnorm
neurolog
behavior
symptom
rare
result
death
mostli
among
children
report
come
japan
exist
data
suggest
event
like
secondari
influenza
infect
oseltamivir
therapi
current
recommend
patient
monitor
close
behavior
abnorm
clinic
signific
drug
interact
recogn
date
includ
studi
amoxicillin
aspirin
acetaminophen
interact
cytochrom
enzym
occur
vitro
oseltamivir
affect
steadyst
pharmacokinet
commonli
use
immunosuppress
agent
howev
probenecid
block
tubular
secret
doubl
halflif
oseltamivir
protein
bind
less
peramivir
low
oral
bioavail
therefor
deliv
intraven
peramivir
achiev
except
high
maximum
concentr
ngml
intraven
dose
excel
concentr
drug
nasal
pharyng
secrect
peramivir
predomin
elimin
unchang
renal
excret
plasma
termin
elimin
halflif
hour
outsid
unit
state
peramivir
avail
solut
intraven
use
wherea
peramivir
avail
solut
intraven
use
unit
state
peramivir
approv
singledos
infus
treatment
previous
healthi
adult
uncompl
influenza
unit
state
nonetheless
studi
treatment
complic
influenza
hospit
adult
intraven
therapi
current
approv
treatment
influenza
placebocontrol
studi
singl
infus
peramivir
associ
significantli
shorter
time
allevi
symptom
significantli
shorter
time
resumpt
patient
usual
activ
rapid
clearanc
viru
singl
infus
peramivir
also
noninferior
day
oral
oseltamivir
mg
twice
day
season
mani
virus
resist
oseltamivir
result
mutat
data
challeng
efficaci
peramivir
manag
virus
mutat
peramivir
also
investig
sever
studi
hospit
adult
children
specif
approv
indic
studi
multipl
dose
peramivir
use
find
suggest
singledos
therapi
appropri
sever
ill
patient
first
studi
conduct
japan
random
highrisk
patient
diabet
chronic
respiratori
tract
diseas
patient
treat
drug
suppress
immun
function
receiv
mg
mg
peramivir
daili
durat
treatment
day
base
clinic
improv
defin
resolut
fever
judgment
princip
investig
subinvestig
continu
administr
unnecessari
median
durat
influenza
symptom
hour
group
hour
group
hazard
ratio
confid
interv
similar
trend
time
resolut
fever
subsequ
studi
larger
random
multin
studi
phase
studi
day
mg
mg
peramivir
everi
day
compar
oral
oseltamivir
mg
twice
day
hospit
adult
trend
toward
rapid
resumpt
usual
activ
peramivirtr
patient
greater
reduct
influenza
b
viral
titer
nasopharynx
oseltamivir
first
hour
phase
multidos
regimen
openlabel
multin
random
studi
start
pandem
octob
octob
design
compar
safeti
toler
dose
regimen
peramivir
hospit
patient
twohundr
thirtyfour
patient
random
receiv
day
mg
peramivir
twice
daili
mg
peramivir
daili
overal
time
clinic
resolut
ttcr
hour
intenttotreat
infect
itti
group
median
time
hour
group
hour
group
subject
regimen
itti
analysi
note
higher
need
supplement
oxygen
random
higher
baselin
apach
score
higher
need
icu
admiss
random
subject
random
regimen
multivari
analysi
show
differ
ttcr
group
could
explain
differ
sever
ill
random
virolog
respons
measur
timeweight
chang
viru
titer
baselin
hour
tcid
median
tissu
cultur
infecti
dose
ml
without
signific
differ
two
dose
p
addit
treatment
differ
seen
percentag
subject
remain
cultur
posit
revers
transcript
polymeras
chain
reaction
posit
hour
postenrol
second
phase
iii
studi
doubleblind
random
trail
conduct
septemb
novemb
enrol
patient
patient
random
receiv
peramivir
standard
care
ratio
patient
confirm
influenza
receiv
nai
neuraminidas
inhibitor
part
standard
care
soc
ittinonnai
group
random
placebo
n
peramivir
n
patient
confirm
influenza
receiv
nai
part
soc
ittinai
group
random
placebo
n
peramivir
n
note
import
differ
ittinonnai
group
ittinai
group
name
lower
mean
bodi
mass
index
vs
kgm
lower
influenza
vaccin
rate
vs
ittinonnai
group
addit
nonnai
soc
subject
shorter
symptom
durat
vs
symptom
hour
less
like
smoke
vs
abnorm
chest
radiograph
baselin
vs
requir
supplement
oxygen
vs
measur
viru
titer
baselin
vs
studi
termin
futil
interim
analysi
peramivirtr
subject
nonnai
soc
popul
show
modest
static
signific
p
improv
ttcr
compar
subject
receiv
soc
alon
vs
hour
similar
result
observ
nai
soc
popul
peramivir
vs
placebo
vs
hour
p
largest
pediatr
studi
multicent
openlabel
uncontrol
studi
pandem
onehundr
six
pediatr
subject
age
day
year
confirm
influenza
receiv
intraven
peramivir
infus
mgkg
mg
maximum
daili
clinic
respons
advers
event
pharmacokinet
assess
median
time
resolut
fever
hour
time
resolut
symptom
hour
viral
clearanc
day
treatment
note
ttcr
pediatr
studi
shorter
time
note
adult
trial
taken
togeth
result
suggest
intraven
peramivir
like
similar
efficaci
oral
oseltamivir
consid
altern
oral
therapi
patient
take
oral
therapi
oral
absorpt
question
peramivir
renal
clear
dose
must
adjust
base
renal
function
see
tabl
limit
data
guid
dose
peramivir
children
particularli
among
neonat
dose
adjust
need
hepat
impair
recogn
advers
event
associ
administr
peramivir
diarrhea
nausea
vomit
decreas
neutrophil
count
less
common
advers
event
observ
studi
date
includ
dizzi
headach
somnol
nervous
insomnia
feel
agit
depress
nightmar
hyperglycemia
hyperbilirubinemia
increas
blood
pressur
cystiti
electrocardiogram
abnorm
anorexia
proteinuria
oral
bioavail
zanamivir
low
clinic
trial
use
intranas
dri
powder
inhal
deliveri
follow
inhal
dri
powder
approxim
deposit
lower
respiratori
tract
remaind
oropharynx
median
zanamivir
concentr
ng
ml
induc
sputum
hour
inhal
remain
detect
hour
peak
plasma
concentr
averag
mgl
singl
inhal
zanamivir
proprietari
inhal
devic
deliv
zanamivir
breath
actuat
requir
cooper
patient
intraven
zanamivir
display
linear
dose
kinet
volum
distribut
approxim
equival
extracellular
water
l
intraven
zanamivir
provid
high
peak
plasma
concentr
ngml
dose
adult
nineti
percent
drug
excret
unchang
urin
elimin
halflif
approxim
hour
intraven
zanamivir
clearanc
highli
correl
renal
function
zanamivir
approv
prevent
treatment
acut
uncompl
influenza
ambulatori
adult
children
deliv
inhal
proprietari
breathactiv
devic
diskhal
usual
adult
treatment
dose
inhal
mg
twice
day
day
day
day
prophylaxi
intraven
zanamivir
current
avail
compassion
use
oncedaili
inhal
zanamivir
day
week
effect
prevent
laboratoryconfirm
symptomat
influenza
zanamivir
indic
treatment
uncompl
acut
ill
caus
influenza
b
virus
adult
pediatr
patient
year
age
older
symptomat
day
inhal
zanamivir
adult
consist
shown
least
less
day
disabl
influenza
symptom
studi
found
reduct
number
night
disturb
sleep
time
resumpt
normal
activ
use
symptom
relief
medic
similar
therapeut
benefit
also
shown
children
age
year
zanamivir
also
associ
reduct
lower
respiratori
tract
complic
influenza
lead
antibiot
particularli
bronchiti
pneumonia
zanamivir
seem
gener
well
toler
effect
treat
influenza
patient
mild
moder
asthma
less
often
chronic
obstruct
pulmonari
diseas
intraven
zanamivir
advanc
clinic
develop
use
serious
ill
patient
influenza
especi
suspect
oseltamivirresist
variant
emerg
investig
new
drug
use
intraven
zanamivir
patient
clinic
fail
antivir
therapi
least
patient
proven
clinic
suspect
resist
oseltamivir
patient
die
phase
studi
critic
ill
patient
pandem
found
treatment
associ
signific
antivir
effect
even
though
therapi
initi
median
day
symptom
onset
patient
influenza
detect
initi
sampl
day
therapi
associ
median
log
copi
per
millilit
declin
viral
load
drugrel
trend
safeti
paramet
identifi
allcaus
mortal
respect
phase
studi
compar
intraven
zanamivir
oral
oseltamivir
hospit
adult
recent
complet
result
avail
time
write
dose
adjust
necessari
renal
hepat
dysfunct
certain
popul
particularli
young
frail
cognit
impair
patient
may
difficulti
use
drug
deliveri
system
intraven
zanamivir
requir
dose
adjust
renal
insuffici
patient
receiv
initi
load
dose
mainten
dose
dose
interv
reduc
worsen
renal
function
dose
accord
updat
guidanc
provid
compassion
use
drug
topic
appli
zanamivir
gener
well
toler
control
studi
includ
involv
patient
asthma
chronic
obstruct
pulmonari
diseas
postmarket
report
indic
bronchospasm
may
uncommon
potenti
sever
problem
particularli
patient
acut
influenza
underli
reactiv
airway
diseas
anecdot
report
hospit
fatal
indic
inhal
zanamivir
use
cautious
patient
current
avail
inhal
formul
use
patient
ventil
obstruct
filter
death
patient
report
one
random
control
trial
ambulatori
adult
found
combin
inhal
zanamivir
oral
oseltamivir
less
effect
oseltamivir
monotherapi
zanamivir
associ
teratogen
effect
preclin
studi
us
food
drug
administr
pregnanc
categori
c
consid
option
pregnant
women
proven
influenza
ribavirin
ribavirin
virazol
rebetol
guanosin
analogu
wide
rang
antivir
activ
includ
influenza
virus
rsv
parainfluenza
virus
ribavirin
rapidli
phosphoryl
intracellular
enzym
triphosph
inhibit
influenza
viru
rna
polymeras
activ
competit
inhibit
guanosin
triphosphatedepend
cap
influenza
viral
messeng
rna
addit
ribavirin
deplet
cellular
guanin
pool
may
inhibit
viru
replic
lethal
mutagenesi
oral
ribavirin
bioavail
adult
children
achiev
peak
plasma
concentr
mgml
hour
ingest
dose
adult
ribavirin
short
initi
hour
long
termin
hour
phase
halflif
elimin
hepat
metabol
renal
clearanc
aerosol
administr
plasma
level
increas
exposur
rang
mgml
respiratori
secret
level
mgml
declin
halflif
hour
ribavirin
avail
formul
oral
approv
combin
use
hepat
c
intraven
investig
unit
state
aerosol
ribavirin
aerosol
avail
solut
ml
dilut
final
concentr
mgml
deliv
small
particl
aerosol
hour
proprietari
devic
nebul
higher
concentr
aerosol
solut
mgml
given
hour
time
daili
studi
seem
well
toler
ribavirin
also
come
tablet
steril
solut
inject
ribavirin
aerosol
current
indic
treatment
sever
rsv
children
trial
aerosol
ribavirin
treatment
sever
rsv
infect
infant
shown
consist
effect
durat
hospit
time
mortal
pulmonari
function
current
guidelin
recommend
aerosol
ribavirin
consid
treatment
highrisk
infant
young
children
defin
congenit
heart
diseas
chronic
lung
diseas
immunodefici
state
prematur
age
less
week
well
hospit
sever
ill
aerosol
ribavirin
shown
minim
efficaci
treat
influenza
hospit
children
ribavirin
also
studi
treatment
rsv
parainfluenza
viru
infect
immunocompromis
patient
intraven
ribavirin
seem
ineffect
reduc
rsvassoci
mortal
hematopoiet
stem
cell
transplant
hsct
patient
rsv
pneumonia
may
benefit
among
lung
transplant
recipi
aerosol
ribavirin
may
provid
benefit
select
patient
group
less
sever
rsv
diseas
surviv
improv
treatment
start
respiratori
failur
infect
limit
upper
respiratori
tract
observ
studi
suggest
combin
therapi
antibodi
either
intraven
immunoglobulin
respigam
palivizumab
seem
effect
particularli
start
sever
respiratori
distress
oral
ribavirin
tri
manag
rsv
variabl
success
manag
parainfluenza
viru
bone
marrow
transplant
recipi
case
seri
found
aerosol
ribavirin
fail
improv
mortal
reduc
durat
viral
replic
rel
treatment
ribavirin
clearli
shown
consist
clinic
activ
treatment
adenoviru
infect
recommend
indic
system
ribavirin
contraind
patient
creatinin
clearanc
less
mlmin
dose
reduc
onethird
patient
less
year
age
dose
adjust
need
substanti
declin
hematocrit
drug
discontinu
hemoglobin
level
decreas
less
gdl
system
ribavirin
caus
doserel
extravascular
hemolyt
anemia
higher
dose
suppress
bone
marrow
releas
erythroid
element
aerosol
ribavirin
caus
bronchospasm
mild
conjunctiv
irrit
rash
psycholog
distress
administ
oxygen
tent
rare
acut
water
intox
bolu
intraven
administr
may
caus
rigor
antagon
drug
may
occur
ribavirin
combin
zidovudin
ribavirin
contraind
pregnant
women
male
partner
women
pregnant
teratogen
drug
pregnanc
avoid
therapi
month
complet
therapi
femal
patient
femal
partner
male
patient
take
ribavirin
pregnanc
categori
x
nitazoxanid
antiparasit
agent
appar
antivir
activ
includ
influenza
viru
noroviru
mechan
action
nitazoxanid
influenza
virus
blockag
matur
viral
hemagglutinin
posttransl
stage
nitazoxanid
reduc
symptom
durat
phase
trial
adult
adolesc
uncompl
influenza
phase
trial
underway
drug
also
show
clinic
efficaci
small
random
trial
viral
gastroenter
cidofovir
antivir
agent
specif
approv
treatment
adenoviru
cidofovir
potent
inhibitor
adenoviru
cell
cultur
use
either
mgkg
weekli
week
everi
week
mgkg
time
week
data
suggest
efficacytox
predominantli
nephrotox
ratio
narrow
result
use
limit
gener
patient
signific
evid
dissemin
adenoviru
diseas
preemptiv
treatment
pediatr
hsct
patient
persist
replic
earlier
onset
therapi
gener
associ
best
result
failur
develop
signific
log
greater
reduct
adenoviru
load
within
week
initi
therapi
gener
associ
poor
outcom
combin
therapi
combin
therapi
studi
use
varieti
combin
antivir
adjunct
therapi
hope
improv
antivir
activ
improv
clinic
outcom
reduc
risk
develop
antivir
resist
influenza
evid
vitro
synergi
addit
effect
oseltamivir
amantadin
oseltamivir
favipiravir
peramivir
rimantadin
peramivir
oseltamivir
tripl
combin
amantadin
ribavirin
oseltamivir
studi
oral
rimantadin
nebul
zanamivir
era
viru
suscept
inhibitor
combin
associ
trend
toward
faster
cough
resolut
lesser
risk
adamantan
resist
emerg
combin
oseltamivir
either
convalesc
plasma
hyperimmun
globulin
associ
reduc
mortal
compar
patient
treat
oseltamivir
alon
studi
oseltamivir
sirolimu
corticosteroid
likewis
associ
reduc
mortal
among
critic
ill
patient
tripl
combin
amantadin
ribavirin
oseltamivir
found
similar
pk
pharmacokinet
individu
antivir
monotherapi
follow
singl
dose
administ
safe
immunocompromis
patient
addit
clinic
studi
tripl
combin
current
underway
likewis
combin
oseltamivir
nitazoxanid
studi
time
write
studi
complet
result
made
public
despit
theoret
benefit
optim
use
combin
therapi
still
investig
similarli
combin
therapi
typic
ribavirin
plu
antibodi
prepar
also
studi
treatment
rsv
parainfluenza
viru
immunocompromis
patient
rsv
lowest
rate
progress
lower
tract
diseas
lowest
mortal
observ
combin
aerosol
ribavirin
antibodi
prepar
either
rsv
immunoglobulin
intraven
immunoglobulin
palivizumab
favipiravir
favipiravir
broad
antivir
seem
inhibit
rnadepend
rna
polymeras
mammalian
rna
dna
synthesi
approv
japan
treatment
influenza
select
circumst
phase
studi
exjapan
treatment
acut
uncompl
influenza
recent
complet
result
pend
antivir
vitro
activ
sever
rna
virus
includ
west
nile
viru
dengu
viru
yellow
fever
viru
ebola
fludas
recombin
fusion
protein
cleav
sialic
acid
residu
respiratori
epitheli
cell
surfac
prevent
influenza
parainfluenza
viral
infect
phase
trial
show
reduct
influenza
viral
load
healthi
adult
limit
impact
symptom
also
use
treat
sever
immunocompromis
patient
piv
infect
complet
partial
respons
shown
patient
phase
random
trial
immunocompromis
host
piv
lower
respiratori
tract
infect
ongo
presatovir
oral
rsv
entri
inhibitor
show
reduct
viral
load
clinic
sever
phase
studi
phase
trial
underway
hospit
patient
adult
hsct
lung
transplant
recipi
nucleosid
analogu
target
rsv
polymeras
show
reduct
viral
load
decreas
diseas
sever
human
challeng
model
studi
hospit
infant
ongo
small
interf
rna
effect
challeng
model
reduc
cumul
daili
symptom
score
incid
progress
bronchiol
obliteran
syndrom
lung
transplant
recipi
current
ongo
clinic
develop
